Rigel Announces First Quarter 2018 Financial Results and Provides Company Update May 01, 2018 4:01pm EDT
TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo Apr 30, 2018 7:30am EDT
Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results Apr 24, 2018 7:30am EDT
Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients Apr 17, 2018 4:51pm EDT
Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy Apr 03, 2018 7:00am EDT
Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update Mar 06, 2018 4:01pm EST
Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America Mar 01, 2018 7:30am EST
